Back to results
US 2020/0199190 A1Published application
Calcitonin Mimetics for Treating Diseases and Disorders
AssigneeKeyBioscience AG
InventorsKim Henriksen, Morten Karsdal, Kim V. Andreassen
Life of this patent
Estimating the term…
Abstract
The present invention relates to humanised calcitonin mimetics and their use in treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poor regulation of food intake.
Claims14
1:
- A peptide, wherein the peptide is:
- (SEQ ID NO:
- 26)
- CGNLSTC LGRL QD X4K TFP TDVGANAP
- wherein
- X1=M or V
- X2=T or S
- X3=F or L
- X4=N or H,
- X5=F or L
- X6=Q or H
- X7=Q or K
9 more elements
2:
- The peptide according to claim 1, wherein X2 is T, X3 is L, X4 is N, X5 is F, X6 is H, and/or X7 is K.
3:
- A peptide according to claim 1, wherein X4 is N, X5 is F, and X6 is H.
4:
- The peptide according to claim 1, wherein the peptide has an identity to human calcitonin of at least 65%.
5:
- The peptide according to claim 1, wherein the peptide is selected from the group consisting of:
- (SEQ ID NO:
- 12)
- CGNLSTCMLGRLSQDLNKFHTFPKTDVGANAP,
- (SEQ ID NO:
- 18)
- CGNLSTCMLGRLTQDLHKLQTFPKTDVGANAP,
- (SEQ ID NO:
- 20)
- CGNLSTCMLGRLTQDFHKLHTFPKTDVGANAP,
- (SEQ ID NO:
- 24)
- CGNLSTCMLGRLTQDLNKFHTFPKTDVGANAP,
- and [[or]]
- (SEQ ID NO:
- 25)
- CGNLSTCMLGRLSQDLNKFHTFPQTDVGANAP
14 more elements
6:
- The peptide as claimed in claim 1, formulated for enteral administration.
7:
- The peptide as claimed in claim 1, formulated for parenteral administration.
8:
- The peptide as claimed in claim 7, formulated for injection.
9:
- The peptide as claimed in claim 1, formulated with a carrier for oral administration.
10:
- The peptide as claimed in claim 9, wherein the carrier comprises N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), sodium salt of 10-(2-Hydroxybenzamido)decanoic acid (SNAD), or sodium salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC).
11:
- A pharmaceutical composition comprising the peptide of claim 6 coated with citric acid particles wherein the coated citric acid particles increase the oral bioavailability of the peptide.
12:
- (canceled)
13:
- A method for treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poor regulation of food intake comprising administering the peptide as claimed in claim 1.
14:
- The method as claimed in claim 13, comprising administering the peptide in conjunction with metformin or another insulin sensitizer.